Implications of the fragility of opioid agonist treatment continuity on hepatitis C re-exposure concerns among people in prison: a qualitative study
Continuity of OAT and HCV care remains a fragile experience for people who cycle in and out of incarceration. People who miss their OAT appointment in the community might wait several months upon re-incarceration to re-enter the OAT program. This leaves people vulnerable to injection sharing in custody and, subsequently, increased risk of HCV (re-)exposure while waiting to recommence OAT or to return to the optimal dosing level.
Authors
- Andrew R. Lloyd (ORCID: https://orcid.org/0000-0001-6277-8887)
- Thomas A. Wright (ORCID: https://orcid.org/0000-0002-7955-5679)
- C. R. Henderson (ORCID: https://orcid.org/0000-0001-7264-2676)
- Lise Lafferty (ORCID: https://orcid.org/0000-0002-8533-2957)
- Tracey J. Brown (ORCID: https://orcid.org/0000-0003-4381-5974)
- Jason Grebely (ORCID: https://orcid.org/0000-0002-1833-2017)
- Carla Treloar (ORCID: https://orcid.org/0000-0002-8230-0386)
- Colette McGrath
Institutions
- New South Wales Department of Health (AU)
- Burnet Institute (AU)
- UNSW Sydney (AU)
- New South Wales Institute of Psychiatry (AU)
- Services Australia (AU)
Publication Details
- Journal
- International Journal of Drug Policy
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1016/j.drugpo.2025.104831
- Citations
- 1
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- University of New South Wales
- NSW Ministry of Health